La cadena de opciones muestra datos clave de las opciones de acciones de Ucloudlink Group a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Ucloudlink Group..

Ucloudlink Group (NASDAQ:UCL) Bolsa, Cadena de Opciones

Ucloudlink Group

Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ALVO

BBGI

BCAX

ELTX

FOXO

ISPC

JBHT

LYTS

MDXG

NATR

NUKK

OFIX

TMCI

TXNM

VIAV

WILC

Explora los mayores ganadores y perdedores en las operaciones previas al mercado. Descubre qué impulsó estos movimientos destacados.

Las acciones de Versus Systems (VS) aumentan un 71%; 20 acciones que se mueven en el premercado de EE.UU.

uCloudlink Group Inc. - American Depositary Shares

Ucloudlink Group Inc

US Nuclear Corp

ULTRATECH CEMENT S/GDR by Ultratech Cement Ltd.

UltraTech Cement Ltd

ULTRATECH CEMENT GDR 144A by Ultratech Cement Ltd.

Baird analyst Andrew Wittmann upgrades ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) from Neutral to Outperform and maintains the price target from $56 to $56.

Upgrades

Price Target

Analyst Ratings

Baird Upgrades ABM Indus to Outperform, Maintains Price Target to $56

Omada Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMDA#NASDAQ">OMDA</a>) closed its first day of trading at $23 per share on Friday, a 21% jump from the IPO price of $19 per share.
On Thursday, Omada Health <a href="https://www.businesswire.com/news/home/20250605376361/en/Omada-Health-Announces-Pricing-of-Initial-Public-Offering" target="_blank" rel="noreferrer noopener">priced</a> its initial public offering of 7.9 million at $19/share. The company filed its initial prospectus in May and updated the document with an expected pricing range of $18 to $20 per share. 
The company raised $150 million in its IPO. Reuters reported Omada Health&#8217;s valuation hit $1.28 billion.
Omada&#8217;s revenue increased 57% in the first quarter of 2025 to $55 million from $35.1 million a year earlier, according to its prospectus. For 2024, revenue rose 38% to $169.8 million from $122.8 million the previous year.
Also Read: <a href="https://www.benzinga.com/news/ipos/25/05/45581582/hinge-health-skyrockets-on-wall-street-debut-signals-comeback-for-health-tech-ipos-tilts-things-towards-potentially-more-listings-says-analyst" target="_blank" rel="noreferrer noopener">Hinge Health Skyrockets On Wall Street Debut, Signals Comeback For Health-Tech IPOs: &#8216;&#8230;Tilts Things&#8230;Towards Potentially More Listings,&#8217; Says Analyst</a>
The company&#8217;s net loss narrowed to $9.4 million in the first quarter from $19 million a year ago.
Omada launched its initial virtual program in <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">diabetes prevention and weight health</a> in 2012.
The company delivers virtual care between doctor visits, providing an engaging, personalized, and integrated experience for members designed to improve their health while delivering value for employers, health plans, health systems, pharmacy benefit managers (PBMs), and other entities that cover the cost of programs.
According to its <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1611115/000119312525129904/d785770ds1a.htm" rel="noreferrer noopener">S-1</a> filing, the company had 2,000 customers and more than 679,000 members enrolled in one or more programs as of 31 March. Omada says it has supported more than 1 million members since its launch.
The company expanded its virtual care programs to target prediabetes, hypertension, and musculoskeletal conditions.
The company estimates that about 20 million people have benefits coverage for one or more Omada programs. According to the company&#8217;s S-1 filing, this represents about 14% of the self-insured insurance market, 9% of the fully insured market, 1% of the Medicare Advantage market, and 1% of the PBM market.
Wall Street Journal, citing President Wei-Li Shao, writes that Omada leadership sees the current moment as the perfect time for an IPO, as GLP-1 drugs such as Ozempic, Wegovy, and Mounjaro have sparked a renewed focus on health problems that can stem from obesity.
GLP-1s are expected to be a significant tailwind as more employers are rolling out reimbursement plans for the drugs, CEO&nbsp;Sean Duffy <a target="_blank" href="https://www.wsj.com/health/pharma/omada-health-ipo-to-price-at-19-a-share-as-glp-1s-fuel-interest-becac4b7" rel="noreferrer noopener">told</a> WSJ. Omada, which signs contracts with employers to offer as a benefit to their workers, aims to be a complementary service that helps patients navigate taking GLP-1s.
Omada&#8217;s IPO is the second digital health IPO in weeks following an extended drought for the industry.
In May, digital physical therapy startup Hinge Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HNGE#NYSE">HNGE</a>) debuted on the <a href="https://www.benzinga.com/pressreleases/25/05/b45555364/hinge-health-announces-pricing-of-initial-public-offering" target="_blank" rel="noreferrer noopener">New York Stock Exchange</a>. Hinge Health priced its IPO of 13.7 million shares at $32 per share.
Price Action: OMDA stock is trading lower by 0.43% to $22.90 premarket at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45830632/ex-goldman-executive-on-circles-168-ipo-spike-dont-rush-to-buy-stock-as-bankers-engineer-a-pop-cites-facebook-example" target="_blank" rel="noreferrer noopener">Ex-Goldman Executive On Circle&#8217;s 168% IPO Spike: Don&#8217;t Rush To Buy Stock As Bankers Engineer A &#8216;Pop&#8217; — Cites Facebook Example</a></li>
</ul>
Photo via Shutterstock

Health Care

IPOs

General

HNGE

OMDA

Virtual Care Firm Omada Health Leverages GLP-1 Trend For $150 Million NASDAQ Debut

Keybanc analyst Bradley Thomas maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Overweight and raises the price target from $105 to $110.

Keybanc Maintains Overweight on Walmart, Raises Price Target to $110

KLTO

Klotho Neurosciences Shares Resume Trade

U.S. stocks traded mixed this morning, with the Dow Jones index falling around 0.2% on Monday.
Following the market opening Monday, the Dow traded down 0.23% to 42,664.42 while the NASDAQ gained 0.05% to 19,538.86. The S&amp;P 500 also fell, dropping, 0.10% to 5,994.22.
Check This Out: <a href="https://www.benzinga.com/news/25/06/45834978/jim-cramer-says-kinder-morgan-is-good-calls-this-communication-services-stock-a-winner">Jim Cramer Says Kinder Morgan Is &#8216;Good,&#8217; Calls This Communication Services Stock A &#8216;Winne</a>r&#8217;
Leading and Lagging Sectors Information technology shares jumped by 0.6% on Monday.
In trading on Monday, utilities stocks fell by 0.8%.
Top Headline
Motorcar Parts of America, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPAA#NASDAQ">MPAA</a>) posted better-than-expected earnings for the fourth quarter on Monday.
The company posted adjusted earnings of 28 cents per share, beating market estimates of 20 cents per share. The company's quarterly sales came in at $193.10 million, versus expectations of $190.70 million.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Klotho Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares shot up 311% to $0.8430 after the company said gene therapy boosted lifespan by 20% in mice, eyes anti-aging breakthrough.</li>
<li>Shares of Know Labs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNW#NYSE">KNW</a>) got a boost, surging 103% to $3.1701. Know Labs shares jumped 205% on Friday after the company announced that entered into an agreement to be acquired by Goldeneye 1995. Also, the company announced a Bitcoin treasury strategy.</li>
<li>Twin Hospitality Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWNP#NASDAQ">TWNP</a>) shares were also up, gaining 61% to $6.60.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>ReShape Lifesciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares dropped 43% to $2.40 after the company announced the pricing of an offering of 1,054,604 shares at $2.50 per share.</li>
<li>Shares of Nuwellis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) were down 41% to $0.2373 after the company announced the pricing of a $4.3 million offering of 406,755 shares and approximately 14 million pre-funded warrants with series A and B Warrants at $0.30 per unit.</li>
<li>The Children&#8217;s Place, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLCE#NASDAQ">PLCE</a>) was down, falling 28% to $4.9101 as the company posted weaker-than-expected results for its first quarter after the closing bell on Friday.</li>
</ul>
Commodities In commodity news, oil traded down 0.2% to $64.44 while gold traded down 0.2% at $3,339.40.
Silver traded up 1.2% to $36.575 on Monday, while copper rose 1.2% to $4.9070.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.1%, while Spain's IBEX 35 Index fell 0.1%. London's FTSE 100 slipped 0.2%, Germany's DAX 40 fell 0.6% and France's CAC 40 fell 0.2% during the session.
Asia Pacific Markets
Asian markets closed higher on Monday, with Japan's Nikkei gaining 0.92%, Hong Kong's Hang Seng Index jumping 1.63%, China's Shanghai Composite gaining 0.43% and India's BSE Sensex gaining 0.31%.
Economics
U.S. wholesale inventories rose 0.2% month-over-month for April.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/06/45835438/top-3-financial-stocks-that-may-collapse-in-june">Top 3 Financial Stocks That May Collapse In June</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

MPAA

NUWE

PLCE

RSLS

TWNP

US Stocks Mixed; Motorcar Parts of America Posts Upbeat Earnings

Shareholders as at the ex-dividend date of 12 June 2025 will be eligible to receive any potential special dividend distributions relating to Tembo transactions&nbsp;
Corresponding record date will be 13 June 2025
LONDON, June 09, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVPR#NASDAQ">VVPR</a>, "VivoPower" or the "Company"))) today announced that it has set an ex-dividend date of 12 June 2025 pertaining to any potential future dividend distributions regarding transactions involving Tembo e LV B.V. ("Tembo").
Shareholders who hold VivoPower shares as of the close of business on 12 June 2025 will be entitled to receive any potential future special dividend distributions relating to Tembo. Shareholders purchasing VivoPower shares on or after the ex-dividend date will not be eligible for the distribution.
Any potential future special dividend distributions relating to the Caret business unit will be advised separately.
Further details regarding potential special dividend distributions, including the amount and ratio will be provided when appropriate. There is no guarantee that any special dividend distributions will be made.

Dividends

VVPR

VivoPower Sets June 12, 2025 Ex-Dividend Date And June 13 Record Date For Potential Special Dividend Distributions Tied To Tembo Transactions

Smith+Nephew ((LSE:SN, NYSE:<a href="https://www.benzinga.com/stock/SNN#NYSE">SNN</a>), the global medical technology company, today announces the introduction of a new medial stabilized insert for its LEGION Total Knee System (TKS). Medial stabilized inserts are seeing a steep rise in popularity, growing from 4% of Total Knee Arthroplasty procedures in 2018 to 32% in 2023.
With the ability to be used with or without the Posterior Cruciate Ligament (PCL), procedural trends are moving away from Posterior Stabilized (PS) design types to more bone-conservative Cruciate Retaining (CR) femoral designs. The reduction of operating steps also creates the potential for greater efficiency and shorter time in the OR for both surgeon and patient.&nbsp;
The medial stabilized design aims to maintain stability with a larger anterior medial lip and medial pivot kinematics similar to the natural knee.
The medial stabilized insert for LEGION TKS is available in the US on a limited basis, with a full commercial release later in 2025. The system will also be introduced in Canada in 2026.

Smith+Nephew Introduces New Medial Stabilized Insert For LEGION Total Knee System

Keybanc analyst Jeffrey Hammond maintains Gates Industrial Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTES#NYSE">GTES</a>) with a Overweight and raises the price target from $23 to $26.

GTES

Keybanc Maintains Overweight on Gates Industrial Corp, Raises Price Target to $26

Investors with a lot of money to spend have taken a bullish stance on CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CRWD, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 17 uncommon options trades for CrowdStrike Holdings.
This isn't normal.
The overall sentiment of these big-money traders is split between 41% bullish and 35%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $184,070, and 14 are calls, for a total amount of $483,833.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $150.0 to $480.0 for CrowdStrike Holdings over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for CrowdStrike Holdings options trades today is 719.53 with a total volume of 541.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for CrowdStrike Holdings's big money trades within a strike price range of $150.0 to $480.0 over the last 30 days.
<h3>CrowdStrike Holdings Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749477841_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRWD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$15.8</td>
<td>$14.65</td>
<td>$15.14</td>
<td>$470.00</td>
<td>$75.8K</td>
<td>1.7K</td>
<td align="right">60</td>
</tr>
<tr>
<td>CRWD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$10.8</td>
<td>$9.4</td>
<td>$9.84</td>
<td>$465.00</td>
<td>$73.8K</td>
<td>223</td>
<td align="right">75</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/27/25</td>
<td>$63.0</td>
<td>$60.05</td>
<td>$61.63</td>
<td>$400.00</td>
<td>$61.6K</td>
<td>17</td>
<td align="right">10</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$101.5</td>
<td>$98.5</td>
<td>$100.91</td>
<td>$400.00</td>
<td>$50.4K</td>
<td>25</td>
<td align="right">2</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$50.7</td>
<td>$48.55</td>
<td>$49.64</td>
<td>$420.00</td>
<td>$49.6K</td>
<td>463</td>
<td align="right">10</td>
</tr>
</tbody>
</table>

<h3>About CrowdStrike Holdings</h3>
CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.
Following our analysis of the options activities associated with CrowdStrike Holdings, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of CrowdStrike Holdings</h3>
<ul>
<li>With a trading volume of 455,721, the price of CRWD is down by -0.74%, reaching $464.93.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 79 days from now.</li>
</ul>
<h3>What The Experts Say On CrowdStrike Holdings</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $452.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Raymond James lowers its rating to Outperform with a new price target of $485. 
&#x2A; Maintaining their stance, an analyst from Stifel continues to hold a Buy rating for CrowdStrike Holdings, targeting a price of $480. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on CrowdStrike Holdings, maintaining a target price of $505. 
&#x2A; An analyst from Roth Capital has decided to maintain their Buy rating on CrowdStrike Holdings, which currently sits at a price target of $420. 
&#x2A; An analyst from Bernstein downgraded its action to Market Perform with a price target of $371. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for CrowdStrike Holdings with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

CRWD

CrowdStrike Holdings Options Trading: A Deep Dive into Market Sentiment

Whales with a lot of money to spend have taken a noticeably bullish stance on Hims &amp; Hers Health.
Looking at options history for Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) we detected 12 trades.
If we consider the specifics of each trade, it is accurate to state that 58% of the investors opened trades with bullish expectations and 41% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $56,370 and 10, calls, for a total amount of $1,326,341.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $3.0 and $60.0 for Hims &amp; Hers Health, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Hims &amp; Hers Health stands at 1735.67, with a total volume reaching 1,252.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Hims &amp; Hers Health, situated within the strike price corridor from $3.0 to $60.0, throughout the last 30 days.
<h3>Hims &amp; Hers Health Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749477835_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$52.45</td>
<td>$51.65</td>
<td>$51.96</td>
<td>$3.00</td>
<td>$519.6K</td>
<td>583</td>
<td align="right">80</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$54.05</td>
<td>$51.55</td>
<td>$51.88</td>
<td>$3.00</td>
<td>$415.0K</td>
<td>583</td>
<td align="right">0</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$9.3</td>
<td>$9.2</td>
<td>$9.2</td>
<td>$60.00</td>
<td>$91.9K</td>
<td>3.5K</td>
<td align="right">105</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$10.6</td>
<td>$10.3</td>
<td>$10.42</td>
<td>$60.00</td>
<td>$74.9K</td>
<td>815</td>
<td align="right">98</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/13/25</td>
<td>$2.69</td>
<td>$2.52</td>
<td>$2.69</td>
<td>$55.00</td>
<td>$53.8K</td>
<td>1.9K</td>
<td align="right">436</td>
</tr>
</tbody>
</table>

<h3>About Hims &amp; Hers Health</h3>
Hims &amp; Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.
After a thorough review of the options trading surrounding Hims &amp; Hers Health, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Hims &amp; Hers Health</h3>
<ul>
<li>Trading volume stands at 4,420,543, with HIMS's price down by -1.84%, positioned at $55.29.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 56 days.</li>
</ul>
<h3>Expert Opinions on Hims &amp; Hers Health</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $65.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Needham persists with their Buy rating on Hims &amp; Hers Health, maintaining a target price of $65. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Hims &amp; Hers Health options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health Unusual Options Activity

Investors with a lot of money to spend have taken a bearish stance on Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with WMT, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 14 options trades for Walmart.
This isn't normal.
The overall sentiment of these big-money traders is split between 28% bullish and 64%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $60,580, and 13, calls, for a total amount of $422,435.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $90.0 to $100.0 for Walmart over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Walmart's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Walmart's whale activity within a strike price range from $90.0 to $100.0 in the last 30 days. 
<h3>Walmart Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749477829_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$1.24</td>
<td>$1.18</td>
<td>$1.24</td>
<td>$98.00</td>
<td>$71.6K</td>
<td>2.7K</td>
<td>588</td>
</tr>
<tr>
<td>WMT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$6.1</td>
<td>$6.05</td>
<td>$6.1</td>
<td>$100.00</td>
<td>$60.5K</td>
<td>2.3K</td>
<td>100</td>
</tr>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$0.54</td>
<td>$0.5</td>
<td>$0.5</td>
<td>$100.00</td>
<td>$50.0K</td>
<td>34.2K</td>
<td>4.0K</td>
</tr>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$11.45</td>
<td>$11.4</td>
<td>$11.4</td>
<td>$95.00</td>
<td>$36.4K</td>
<td>1.4K</td>
<td>1</td>
</tr>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$8.5</td>
<td>$8.3</td>
<td>$8.44</td>
<td>$90.00</td>
<td>$33.8K</td>
<td>382</td>
<td>40</td>
</tr>
</tbody>
</table>

<h3>About Walmart</h3>
Walmart is a leading retailer in the United States, with its strategy predicated on superior operating efficiency and offering the lowest priced goods to consumers to drive robust store traffic and product turnover. Walmart augmented its low-price business strategy by offering a convenient one-stop shopping destination with the opening of its first supercenter in 1988.Today, Walmart operates over 4,600 stores in the United States (5,200 including Sam's Club) and over 10,000 locations globally. Walmart generated over $460 billion in domestic namesake sales in fiscal 2025, with Sam's Club contributing another $90 billion to the company's top line. Internationally, Walmart generated $120 billion in sales. The retailer serves around 270 million customers globally each week.
Having examined the options trading patterns of Walmart, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Walmart</h3>
<ul>
<li>Trading volume stands at 1,449,019, with WMT's price down by -0.03%, positioned at $97.44.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 66 days.</li>
</ul>
<h3>Expert Opinions on Walmart</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $112.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Baird keeps a Outperform rating on Walmart with a target price of $110. 
&#x2A; An analyst from Telsey Advisory Group persists with their Outperform rating on Walmart, maintaining a target price of $115. 
&#x2A; Consistent in their evaluation, an analyst from Telsey Advisory Group keeps a Outperform rating on Walmart with a target price of $115. 
&#x2A; An analyst from Evercore ISI Group persists with their Outperform rating on Walmart, maintaining a target price of $107. 
&#x2A; An analyst from DA Davidson persists with their Buy rating on Walmart, maintaining a target price of $117. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Walmart with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

This Is What Whales Are Betting On Walmart

Klotho Neurosciences Shares Halted On Circuit Breaker To The Upside, Stock Now Up 417.1%

MIND Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIND#NASDAQ">MIND</a>) is preparing to release its quarterly earnings on Tuesday, 2025-06-10. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect MIND Technology to report an earnings per share (EPS) of $0.08.
Anticipation surrounds MIND Technology's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Performance in Previous Earnings</h3>
The company's EPS beat by $0.07 in the last quarter, leading to a 26.47% increase in the share price on the following day.
Here's a look at MIND Technology's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2025</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.18</td>
<td>0.13</td>
<td>0.02</td>
<td>0.3</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.25</td>
<td>2.87</td>
<td>-0.11</td>
<td>0</td>
</tr>
<tr>
<td>Price Change %</td>
<td>26.0%</td>
<td>42.0%</td>
<td>5.0%</td>
<td>-20.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1749477784_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of MIND Technology were trading at $6.96 as of June 06. Over the last 52-week period, shares are up 57.37%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/MIND/earnings">To track all earnings releases for MIND Technology visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MIND

MIND Technology's Earnings: A Preview

PetMed Express (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PETS#NASDAQ">PETS</a>) is preparing to release its quarterly earnings on Tuesday, 2025-06-10. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect PetMed Express to report an earnings per share (EPS) of $-0.06.
The announcement from PetMed Express is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS missed by $0.03, leading to a 14.04% drop in the share price on the subsequent day.
Here's a look at PetMed Express's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0</td>
<td>-0.05</td>
<td>-0.09</td>
<td>-0.03</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.03</td>
<td>0.11</td>
<td>0.18</td>
<td>-0.25</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-14.000000000000002%</td>
<td>36.0%</td>
<td>-14.000000000000002%</td>
<td>-11.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1749477770_0.png" alt="eps graph" />
<h3>Performance of PetMed Express Shares</h3>
Shares of PetMed Express were trading at $3.96 as of June 06. Over the last 52-week period, shares are down 15.5%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/PETS/earnings">To track all earnings releases for PetMed Express visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PETS

What to Expect from PetMed Express's Earnings

<ul>
<li>Site would take advantage of existing infrastructure and more than a century of partnership with Anderson County</li>
<li>Proposal will be first request by company to build new generation in the Palmetto State in a decade</li>
<li>Plans support intent by state leaders to address growth and economic success by advancing new electricity capacity in the state</li>
</ul>
GREENVILLE, S.C., June 9, 2025 /PRNewswire/ -- Duke Energy announced today the company's intent to submit an application to the Public Service Commission of South Carolina (PSCSC) for approval to build a new natural gas power plant in Anderson County.

Duke Energy Intends To Submit Application To Public Service Commission Of South Carolina For Approval To Build New Natural Gas Power Plant In Anderson County

WIIM

NISN

NISN stock has given up its prior gain. NiSun Intl Enterprise Development Group shares were trading higher after the company announced expansion into the edible oil trading sector through its newly acquired subsidiary Zhetai Trading.

GitLab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) will release its quarterly earnings report on Tuesday, 2025-06-10. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate GitLab to report an earnings per share (EPS) of $0.15.
The market awaits GitLab's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS beat by $0.10, leading to a 11.64% increase in the share price on the subsequent day.
Here's a look at GitLab's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2025</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.23</td>
<td>0.16</td>
<td>0.10</td>
<td>-0.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.33</td>
<td>0.23</td>
<td>0.15</td>
<td>0.03</td>
</tr>
<tr>
<td>Price Change %</td>
<td>12.0%</td>
<td>2.0%</td>
<td>22.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1749477739_0.png" alt="eps graph" />
<h3>Market Performance of GitLab's Stock</h3>
Shares of GitLab were trading at $48.77 as of June 06. Over the last 52-week period, shares are up 14.44%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Insights Shared by Analysts on GitLab</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on GitLab.
GitLab has received a total of 6 ratings from analysts, with the consensus rating as Outperform. With an average one-year price target of $61.67, the consensus suggests a potential 26.45% upside.
<h3>Peer Ratings Overview</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of CommVault Systems, UiPath and Dolby Laboratories, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for CommVault Systems, with an average 1-year price target of $184.5, suggesting a potential 278.31% upside.</li>
<li>Analysts currently favor an Neutral trajectory for UiPath, with an average 1-year price target of $12.87, suggesting a potential 73.61% downside.</li>
<li>Analysts currently favor an Buy trajectory for Dolby Laboratories, with an average 1-year price target of $102.33, suggesting a potential 109.82% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
Within the peer analysis summary, vital metrics for CommVault Systems, UiPath and Dolby Laboratories are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>GitLab</td>
<td>Outperform</td>
<td>29.10%</td>
<td>$188.56M</td>
<td>0.77%</td>
</tr>
<tr>
<td>CommVault Systems</td>
<td>Outperform</td>
<td>23.17%</td>
<td>$227.27M</td>
<td>10.11%</td>
</tr>
<tr>
<td>UiPath</td>
<td>Neutral</td>
<td>6.42%</td>
<td>$292.77M</td>
<td>-1.27%</td>
</tr>
<tr>
<td>Dolby Laboratories</td>
<td>Buy</td>
<td>1.38%</td>
<td>$333.72M</td>
<td>3.61%</td>
</tr>
</tbody>
</table>

Key Takeaway:
GitLab ranks first in revenue growth among its peers. It has the lowest gross profit margin. GitLab has the lowest return on equity.
<h3>Discovering GitLab: A Closer Look</h3>
GitLab Inc operates on an all-remote model. GitLab, a complete DevSecOps platform delivered as a single application. It operates in two competitive landscapes: DevOps point solutions and DevOps platforms. In terms of point solutions that are stitched together, GitLab's offering is substantially different in that it is one platform, one codebase, one interface, and a unified data model that spans the entire DevSecOps lifecycle. DevOps platforms, the principal competitor is Microsoft Corporation following their acquisition of GitHub. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. It is located in the United States, Europe, and Asia Pacific. It focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
<h3>GitLab: Financial Performance Dissected</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: GitLab displayed positive results in 3 months. As of 31 January, 2025, the company achieved a solid revenue growth rate of approximately 29.1%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: GitLab's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.75% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): GitLab's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 0.77%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.44%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: GitLab's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/GTLB/earnings">To track all earnings releases for GitLab visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GTLB

Preview: GitLab's Earnings

United Natural Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNFI#NYSE">UNFI</a>) will release its quarterly earnings report on Tuesday, 2025-06-10. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate United Natural Foods to report an earnings per share (EPS) of $0.22.
Investors in United Natural Foods are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Performance in Previous Earnings</h3>
Last quarter the company beat EPS by $0.03, which was followed by a 11.6% increase in the share price the next day.
Here's a look at United Natural Foods's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.19</td>
<td>-0.01</td>
<td>-0.10</td>
<td>0.03</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.22</td>
<td>0.16</td>
<td>0.01</td>
<td>0.10</td>
</tr>
<tr>
<td>Price Change %</td>
<td>12.0%</td>
<td>-5.0%</td>
<td>-4.0%</td>
<td>16.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1749477723_0.png" alt="eps graph" />
<h3>Market Performance of United Natural Foods's Stock</h3>
Shares of United Natural Foods were trading at $27.86 as of June 06. Over the last 52-week period, shares are up 89.83%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analyst Observations about United Natural Foods</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on United Natural Foods.
United Natural Foods has received a total of 1 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $33.0, the consensus suggests a potential 18.45% upside.
<h3>Comparing Ratings with Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Andersons, The Chefs' Warehouse and Performance Food Gr, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Andersons, with an average 1-year price target of $50.0, suggesting a potential 79.47% upside.</li>
<li>Analysts currently favor an Buy trajectory for The Chefs' Warehouse, with an average 1-year price target of $68.0, suggesting a potential 144.08% upside.</li>
<li>Analysts currently favor an Buy trajectory for Performance Food Gr, with an average 1-year price target of $104.57, suggesting a potential 275.34% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Andersons, The Chefs' Warehouse and Performance Food Gr, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>United Natural Foods</td>
<td>Buy</td>
<td>4.93%</td>
<td>$1.07B</td>
<td>-0.18%</td>
</tr>
<tr>
<td>Andersons</td>
<td>Buy</td>
<td>-2.17%</td>
<td>$152.87M</td>
<td>0.02%</td>
</tr>
<tr>
<td>The Chefs' Warehouse</td>
<td>Buy</td>
<td>8.72%</td>
<td>$226.00M</td>
<td>1.91%</td>
</tr>
<tr>
<td>Performance Food Gr</td>
<td>Buy</td>
<td>10.45%</td>
<td>$1.82B</td>
<td>1.36%</td>
</tr>
</tbody>
</table>

Key Takeaway:
United Natural Foods ranks: 
- Top for Revenue Growth among peers. 
- Bottom for Gross Profit among peers. 
- Bottom for Return on Equity among peers.
<h3>Get to Know United Natural Foods Better</h3>
United Natural Foods Inc is a wholesale distributor of natural, organic and specialty foods and nonfood products across North America. The company's products consist of national, regional and private label brands grouped into grocery and general merchandise, produce, perishables and frozen foods, nutritional supplements and sports nutrition, bulk and foodservice products, and personal care items. United Natural Foods serves various retail formats including conventional supermarket chains, natural product superstores, independent retail operators and foodservice channels such as e-commerce platforms. The company's operations are comprised of principal divisions: the wholesale division; the retail division; and other.
<h3>United Natural Foods: Financial Performance Dissected</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: United Natural Foods's revenue growth over a period of 3 months has been noteworthy. As of 31 January, 2025, the company achieved a revenue growth rate of approximately 4.93%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Staples sector.
Net Margin: United Natural Foods's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -0.04%, the company may face hurdles in effective cost management.
Return on Equity (ROE): United Natural Foods's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -0.18%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): United Natural Foods's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.04%, the company may face hurdles in achieving optimal financial performance.
Debt Management: United Natural Foods's debt-to-equity ratio is below the industry average at 2.29, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/UNFI/earnings">To track all earnings releases for United Natural Foods visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UNFI

A Preview Of United Natural Foods's Earnings

A young English teacher's unfiltered goodbye is lighting up TikTok — and setting off alarms about the <a href="https://www.benzinga.com/personal-finance/25/05/45139109/this-one-high-school-class-could-be-worth-100000-over-a-lifetime">state of America's high schools</a>.
In a <a href="https://www.tiktok.com/t/ZTjb8tVq7/">raw, viral video</a>, the 10th grade teacher doesn't hold back. After just three years in the classroom, she says she's done — and the reasons go way beyond pay. "This will not be my classroom after Friday," she began. "I am actually leaving the profession."
Why? According to her, it's because kids today can't read, won't write, and don't care. And she blames a mix of factors — from smartphones and AI tools like ChatGPT to a lack of guidance from older generations. "<a href="https://www.benzinga.com/tech/25/04/44857520/bill-gates-says-his-kids-and-grandkids-will-live-in-a-very-changed-world-as-ai-puts-an-end-to-shortage-of-teachers-and-doctors">Technology is directly contributing</a> to the literacy decrease we are seeing in this country right now," she said.
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Wall Street's Missing This AI Surgical Tech — You Don't Have To.<a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution"> Invest from $350.</a></li>
</ul>
She's not talking about toddlers either — these are teenagers. "A lot of kids don't know how to read," she said. "They have had things read to them… These kids don't care. They don't care about making a difference in the world. They don't care about how to write a resume or cover letter — because ChatGPT will do it for them."
She says students roll their eyes and "throw tantrums" when asked to handwrite a basic paragraph. "We're talking five sentences," she said, stunned. "They get really, really unruly."
And movie days? Not what they used to be. "They want a movie on in the background for the noise while they scroll on their phones, put their headphones in, and look at TikTok," she said.
Despite being part of Gen Z herself — born in 1999 — she says she feels like a dinosaur. "Call me old-fashioned. I will be old-fashioned," she said. "But we are at the point where I really don't have a lot of faith in some of these kids that I teach."
Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
The problem, she says, isn't just with students. She puts some of the blame on the adults. "I feel like the older generations have failed them because they haven't emphasized to them enough that learning how to read and write and use basic, basic, basic mathematic skills is important."
She's urging schools to "cut off technology from the kids until they go to college" and reinvest in textbooks, paper, and actual classroom learning — <a href="https://www.benzinga.com/markets/tech/25/06/45766429/openais-srinivas-narayanan-says-chatgpt-is-no-longer-just-conversational-its-now-taking-actions-on-your-behalf">not digital shortcuts</a>. "There is nothing wrong with using your budget on textbooks and workbooks and paper copies of things again," she said. "You've got to start getting rid of the technology and bringing back the things that worked."
Her parting words? "This generation is really tough. And I will admit that I'm just not cut out for it… I commend you. God bless. I wish I was stronger that way, but yeah."
Read Next:
<ul class="wp-block-list">
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.</li>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
</ul>
Image: Shutterstock

Personal Finance

'Kids Don't Care, Can't Read': 10th Grade Teacher Quits, Blames Tech And Parents — Says 'I Don't Have A Lot Of Faith In Some Of These Kids'

ARK Invest founder Cathie Wood is betting big on a new frontier in biotechnology, one she says could unlock massive market opportunity, and two companies are already leading the way, with the potential to grow 10x from their current levels.
What Happened: Speaking on The Diary of a CEO podcast last week, Wood said the convergence of gene sequencing, artificial intelligence and CRISPR gene editing is beginning to cure diseases previously thought untreatable, and it&#8217;s already generating revenue.
&#8220;This is already beginning to happen,&#8221; Wood said. &#8220;We are able to diagnose cancer with a blood test in Stage 1,&#8221; and even before stage 1 she says, adding that if cancer was discovered in &#8220;Stage 1,&#8221; it can save most people. 
Wood highlighted CRISPR Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) and Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) as key beneficiaries of this shift. The two companies co-developed Casgevy, a therapy now approved to treat sickle cell disease and beta thalassemia with a single dose.
See Also: <a href="https://www.benzinga.com/markets/tech/25/06/45831309/why-jeff-bezos-might-emerge-as-the-biggest-winner-in-the-trump-musk-feud">Why Jeff Bezos Might Emerge As The Biggest Winner In The Trump-Musk Feud?</a>
&#8220;There's huge demand,&#8221; Wood said, pointing to the severe burden patients suffering from sickle cell disease and beta thalassemia face from repeated hospitalizations. &#8220;Of course they're going to go through a tough regimen, they want to live a more normal life.&#8221;
Casgevy, she says was approved by U.S. and U.K. regulators in late 2023 and is already generating revenue for both firms. Wood believes this marks the beginning of a longer-term transformation in health care economics, where curative, one-time treatments could replace recurring drug regimens, disrupting traditional pharma revenue models.
Wood concluded by saying the she believes these technologies will go up &#8220;more than tenfold in the next five to 10 years,&#8221; adding that &#8220;the opportunities are going to be enormous.&#8221;
Why It Matters: Ark Invest has been a <a href="https://www.benzinga.com/general/biotech/24/11/42206182/cathie-wood-sees-400b-opportunity-in-biologics-how-have-her-bets-fared">proponent of AI and biologic</a>s for the past several years, having called it a $400 billion opportunity just last year. 
Several other prominent experts and entrepreneurs have <a href="https://www.benzinga.com/general/biotech/23/02/30749615/bill-gates-gets-excited-about-future-of-tech-that-has-revolutionized-health-over-past-decade">espoused similar views</a>. This includes Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) founder Bill Gates, who said that CRISPR techonlogy had already &#8220;revolutionized health over the past decade,&#8221; adding that he was excited to see how it will evolve and intersect with other technologies. 
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td class="has-text-align-center" data-align="center">Stock / ETF</td>
<td class="has-text-align-center" data-align="center">Year-To-Date Performance</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">CRISPR Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>)</td>
<td class="has-text-align-center" data-align="center">+1.04%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>)</td>
<td class="has-text-align-center" data-align="center">+11.03%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)</td>
<td class="has-text-align-center" data-align="center">-4.82%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">ARK Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#BATS">ARKK</a>)</td>
<td class="has-text-align-center" data-align="center">+7.45%</td>
</tr>
</tbody>
</table>
</figure>
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="148" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09055452/Screenshot-2025-06-09-at-3.24.39-PM-1024x148.png" alt="" class="wp-image-942918" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09055452/Screenshot-2025-06-09-at-3.24.39-PM-1024x148.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09055452/Screenshot-2025-06-09-at-3.24.39-PM-300x43.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09055452/Screenshot-2025-06-09-at-3.24.39-PM-768x111.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09055452/Screenshot-2025-06-09-at-3.24.39-PM.png 1522w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
According to Benzinga&#8217;s Edge Stock Rankings, Crispr Therapeutics scores poorly across the board. While it does have a favorable price trend in the short and medium-terms, <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">here&#8217;s</a> how it compares with Vertex, and other promising biotech stocks. 
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="World Leading Investing Expert: The Big Shift Is Coming! This Investment Could 15x in 5 Years!" width="500" height="281" src="https://www.youtube.com/embed/ZznpMh0DegE?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45831613/collapse-in-immigration-poses-a-bigger-economic-threat-than-trumps-tariffs-warns-deutsche-bank-negative-supply-shock-is-not-good-news-for-a-currency">&#8216;Collapse In Immigration&#8217; Poses A Bigger Economic Threat Than Trump&#8217;s Tariffs, Warns Deutsche Bank: &#8216;Negative Supply Shock Is Not Good News For A Currency&#8217;</a></li>
</ul>
Photo courtesy: T. Schneider / Shutterstock.com

ARKG

ARKK

CRSP

MSFT

VRTX

Cathie Wood Just Flagged The Start Of A Biotech Revolution: These 2 Stocks With 10x Potential Are Leading It

Press Releases

UCLOUDLINK Receives Approval for Pilot Operations of Value-Added Telecoms Services from MIIT

UCLOUDLINK GROUP INC. Announces Unaudited Fourth Quarter and Full Year 2024 Financial Results

Diamond Equity Research Releases Update Note on uCloudlink Group Inc.  (NASDAQ: UCL)

UCLOUDLINK's GlocalMe eSIM TRIO Receives SlashGear's "MWC Innovation Award"

UCLOUDLINK GROUP INC. Files 2024 Annual Report on Form 20-F

UCLOUDLINK GROUP INC. to Sponsor the LD Micro Invitational XV April 9-10, 2025

UCLOUDLINK GROUP INC. to Report First Quarter 2025 Financial Results on May 21, 2025

uCloudlink Unveils 4 Breakthrough Solutions at MVNOs World 2025: Driving Revenue, Network Optimization and User Retention for MVNOs

UCLOUDLINK GROUP INC. Announces Unaudited First Quarter 2025 Financial Results

Diamond Equity Research Releases Update Note on uCloudlink Group Inc. (NASDAQ: UCL)

America Movil, S.A.B. de C.V. American Depositary Shares (each representing the right to receive twenty (20) Series B Shares

America Movil

FingerMotion

Gogo

Kore Group Holdings

PLDT

SK Telecom Co

Spok Holdings

Surgepays

Telephone and Data Systems, Inc. Common Shares

Telephone and Data Sys

Millicom International Cellular S.A. - Common Stock

Millicom Intl Cellular

TIM S.A. American Depositary Shares (Each representing 5 Common Shares)

Turkcell Iletisim Hizmetleri AS Common Stock

Turkcell Iletisim

T-Mobile US

United States Cellular Corporation Common Stock

United States Cellular

VEON

Vodafone Group Plc - American Depositary Shares each representing ten Ordinary Shares

Comments

Ucloudlink Group

Ucloudlink Group (UCL) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL